Elevated Aβ aggregates in feces from Alzheimer's disease patients: a proof-of-concept study.
Amyloidosis
Aβ oligomer quantitation
Brain-gut-microbiota axis
Clearance
Fecal/stool samples
Leaky gut
sFIDA
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
received:
27
06
2023
accepted:
05
10
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
14
10
2024
Statut:
epublish
Résumé
Misfolding and aggregation of amyloid β (Aβ), along with neurofibrillary tangles consisting of aggregated Tau species, are pathological hallmarks of Alzheimer's disease (AD) onset and progression. In this study, we hypothesized the clearance of Aβ aggregates from the brain and body into the gut. To investigate this, we used surface-based fluorescence intensity distribution analysis (sFIDA) to determine the Aβ aggregate concentrations in feces from 26 AD patients and 31 healthy controls (HC). Aβ aggregates were detectable in human feces and their concentrations were elevated in AD patients compared to HC (specificity 90.3%, sensitivity 53.8%). Thus, fecal Aβ aggregates constitute a non-invasive biomarker candidate for diagnosing AD. Whether digestion-resistant Aβ aggregates in feces are secreted via the liver and bile or directly from the enteric neuronal system remains to be elucidated.
Sections du résumé
BACKGROUND
BACKGROUND
Misfolding and aggregation of amyloid β (Aβ), along with neurofibrillary tangles consisting of aggregated Tau species, are pathological hallmarks of Alzheimer's disease (AD) onset and progression. In this study, we hypothesized the clearance of Aβ aggregates from the brain and body into the gut.
METHODS
METHODS
To investigate this, we used surface-based fluorescence intensity distribution analysis (sFIDA) to determine the Aβ aggregate concentrations in feces from 26 AD patients and 31 healthy controls (HC).
RESULTS
RESULTS
Aβ aggregates were detectable in human feces and their concentrations were elevated in AD patients compared to HC (specificity 90.3%, sensitivity 53.8%).
CONCLUSION
CONCLUSIONS
Thus, fecal Aβ aggregates constitute a non-invasive biomarker candidate for diagnosing AD. Whether digestion-resistant Aβ aggregates in feces are secreted via the liver and bile or directly from the enteric neuronal system remains to be elucidated.
Identifiants
pubmed: 39402637
doi: 10.1186/s13195-024-01597-3
pii: 10.1186/s13195-024-01597-3
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Protein Aggregates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
223Informations de copyright
© 2024. The Author(s).
Références
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.
Brown MR, Radford SE, Hewitt EW. Modulation of β-Amyloid fibril formation in Alzheimer’s disease by Microglia and infection. Front Mol Neurosci. 2020;13:609073.
doi: 10.3389/fnmol.2020.609073
pubmed: 33324164
pmcid: 7725705
Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The amyloid-β pathway in Alzheimer’s disease. Mol Psychiatry. 2021;26(10):5481–503.
Kulenkampff K, Wolf Perez AM, Sormanni P, Habchi J, Vendruscolo M. Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. Nat Reviews Chem. 2021;5(4):277–94.
Kowalski K, Mulak A. Brain-gut-microbiota Axis in Alzheimer’s Disease. J Neurogastroenterol Motil. 2019;25(1):48–60.
doi: 10.5056/jnm18087
pubmed: 30646475
pmcid: 6326209
Ferreiro AL, et al. Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease. Sci Transl Med. 2023;15(700):eabo2984.
doi: 10.1126/scitranslmed.abo2984
pubmed: 37315112
pmcid: 10680783
Varesi A et al. The Potential Role of Gut Microbiota in Alzheimer’s Disease: From Diagnosis to Treatment. Nutrients, 2022. 14(3).
Laske C, et al. Signature of Alzheimer’s Disease in Intestinal Microbiome: results from the AlzBiom Study. Front Neurosci. 2022;16:792996.
doi: 10.3389/fnins.2022.792996
pubmed: 35516807
pmcid: 9063165
Sun M, Ma K, Wen J, Wang G, Zhang C, Li Q, et al. A review of the brain-gut-microbiome axis and the potential role of microbiota in Alzheimer’s disease. J Alzheimers Dis. 2020;73(3):849–65.
Leblhuber F, et al. Elevated fecal calprotectin in patients with Alzheimer’s dementia indicates leaky gut. J Neural Transm. 2015;122(9):1319–22.
doi: 10.1007/s00702-015-1381-9
pubmed: 25680441
Fink A, Doblhammer G, Tamgüney G. Recurring gastrointestinal infections increase the risk of Dementia. J Alzheimers Dis. 2021;84:797–806.
doi: 10.3233/JAD-210316
pubmed: 34602468
pmcid: 8673498
Cheng Y, Tian DY, Wang YJ. Peripheral clearance of brain-derived Aβ in Alzheimer’s disease: pathophysiology and therapeutic perspectives. Transl Neurodegener. 2020;9(1):16.
doi: 10.1186/s40035-020-00195-1
pubmed: 32381118
pmcid: 7204069
Wang J, Gu BJ, Masters CL, Wang YJ. A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain. Nat Rev Neurol. 2017;13(10):612–23.
Ullah R, et al. Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer’s pathology: insights and therapeutic approaches from periphery. Ageing Res Rev. 2021;71:101451.
doi: 10.1016/j.arr.2021.101451
pubmed: 34450351
Jiang C, et al. The gut microbiota and Alzheimer’s Disease. J Alzheimers Dis. 2017;58(1):1–15.
doi: 10.3233/JAD-161141
pubmed: 28372330
Wu S, Hu L, Lin J, Li K, Ye S, Zhu S, et al. Excretion of amyloid-β in the gastrointestinal tract and regulation by the gut microbiota. J Alzheimers Dis. 2022;90:1153–62.
Pellegrini C et al. Prodromal Intestinal Events in Alzheimer’s Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. Int J Mol Sci, 2020. 21(10).
Manocha GD, Floden AM, Miller NM, Smith AJ, Nagamoto-Combs K, Saito T, et al. Temporal progression of Alzheimer’s disease in brains and intestines of transgenic mice. Neurobiol Aging. 2019;81:166–76.
Puig KL, Manocha GD, Combs CK. Amyloid precursor protein mediated changes in intestinal epithelial phenotype in vitro. PLoS ONE. 2015;10(3):e0119534.
doi: 10.1371/journal.pone.0119534
pubmed: 25742317
pmcid: 4351204
Joachim CL, Mori H, Selkoe DJ. Amyloid beta-protein deposition in tissues other than brain in Alzheimer’s disease. Nature. 1989;341(6239):226–30.
doi: 10.1038/341226a0
pubmed: 2528696
Willbold D, Strodel B, Schröder GF, Hoyer W, Heise H. Amyloid-type protein aggregation and prion-like properties of amyloids. Chem Rev. 2021;121(13):8285–307.
Kulawik A, Heise H, Zafiu C, Willbold D, Bannach O. Advancements of the sFIDA method for oligomer-based diagnostics of neurodegenerative diseases. FEBS Lett. 2018;592(4):516–34.
Herrmann Y, Kulawik A, Kühbach K, Hülsemann M, Peters L, Bujnicki T, et al. sFIDA automation yields sub-femtomolar limit of detection for Aβ aggregates in body fluids. Clin Biochem. 2017;50(4–5):244–7.
Hülsemann M, et al. Biofunctionalized silica nanoparticles: standards in Amyloid-β oligomer-based diagnosis of Alzheimer’s Disease. J Alzheimers Dis. 2016;54(1):79–88.
doi: 10.3233/JAD-160253
pubmed: 27472876
Pils M, Dybala A, Rehn F, Blömeke L, Bujnicki T, Kraemer-Schulien V, et al. Development and implementation of an internal quality control sample to standardize oligomer-based diagnostics of Alzheimer’s disease. Diagnostics. 2023;13(10):1702.
Blömeke L, et al. Quantitative detection of α-Synuclein and tau oligomers and other aggregates by digital single particle counting. NPJ Parkinsons Dis. 2022;8(1):68.
doi: 10.1038/s41531-022-00330-x
pubmed: 35655068
pmcid: 9163356
Wang-Dietrich L, et al. The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer’s disease. J Alzheimers Dis. 2013;34(4):985–94.
doi: 10.3233/JAD-122047
pubmed: 23313925
Schaffrath A, et al. Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool. NPJ Parkinsons Dis. 2023;9(1):14.
doi: 10.1038/s41531-023-00458-4
pubmed: 36732520
pmcid: 9895074
Kass B, et al. Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo. Cell Rep Med. 2022;3(5):100630.
doi: 10.1016/j.xcrm.2022.100630
pubmed: 35584626
pmcid: 9133466
Kalbe E, et al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry. 2004;19(2):136–43.
doi: 10.1002/gps.1042
pubmed: 14758579
Beck AT, et al. Comparison of Beck Depression inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996;67(3):588–97.
doi: 10.1207/s15327752jpa6703_13
pubmed: 8991972
Crook TH 3rd, Feher EP, Larrabee GJ. Assessment of memory complaint in age-associated memory impairment: the MAC-Q. Int Psychogeriatr. 1992;4(2):165–76.
doi: 10.1017/S1041610292000991
pubmed: 1477304
Pfeffer RI, et al. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37(3):323–9.
doi: 10.1093/geronj/37.3.323
pubmed: 7069156
Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.
doi: 10.1016/j.jalz.2011.03.008
pubmed: 21514249
Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920–4.
doi: 10.3109/00365529709011203
pubmed: 9299672
Dornieden S, et al. Characterization of a single-chain variable fragment recognizing a linear epitope of aβ: a biotechnical tool for studies on Alzheimer’s disease? PLoS ONE. 2013;8(3):e59820.
doi: 10.1371/journal.pone.0059820
pubmed: 23555792
pmcid: 3608532
Qian XH, Xie RY, Liu XL, Tang HD. Mechanisms of short-chain fatty acids derived from Gut microbiota in Alzheimer’s disease. Aging Dis. 2022;13(4):1252–66.
Vogt NM, et al. Gut microbiome alterations in Alzheimer’s disease. Sci Rep. 2017;7(1):13537.
doi: 10.1038/s41598-017-13601-y
pubmed: 29051531
pmcid: 5648830
Vandeputte D, et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65(1):57–62.
doi: 10.1136/gutjnl-2015-309618
pubmed: 26069274
Vanderstichele H, et al. Potential sources of interference on Abeta immunoassays in biological samples. Alzheimers Res Ther. 2012;4(5):39.
doi: 10.1186/alzrt142
pubmed: 23082750
pmcid: 3580396
Dimeski G. Interference testing. Clin Biochem Rev. 2008;29(Suppl 1):S43–8.
pubmed: 18852856
pmcid: 2556582
Park JY, Kricka LJ. Chap. 5.3 - interferences in Immunoassay. The Immunoassay Handbook (Fourth Edition). Oxford: Elsevier; 2013. pp. 403–16. D. Wild, Editor.
doi: 10.1016/B978-0-08-097037-0.00027-0
Andreasson U, et al. A practical guide to Immunoassay Method Validation. Front Neurol. 2015;6:179.
doi: 10.3389/fneur.2015.00179
pubmed: 26347708
pmcid: 4541289
Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008;29(Suppl 1):S49–52.
pubmed: 18852857
pmcid: 2556583
van de Merbel N, et al. Stability: recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team. Aaps j. 2014;16(3):392–9.
doi: 10.1208/s12248-014-9573-z
pubmed: 24550081
pmcid: 4012051
Vanderstichele HM, et al. Optimized standard operating procedures for the analysis of Cerebrospinal Fluid Aβ42 and the ratios of Aβ isoforms using low protein binding tubes. J Alzheimers Dis. 2016;53(3):1121–32.
doi: 10.3233/JAD-160286
pubmed: 27258423
pmcid: 4981898
Salvadores N, et al. Detection of misfolded Aβ oligomers for sensitive biochemical diagnosis of Alzheimer’s disease. Cell Rep. 2014;7(1):261–8.
doi: 10.1016/j.celrep.2014.02.031
pubmed: 24656814
Teunissen CE, et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66–77.
doi: 10.1016/S1474-4422(21)00361-6
pubmed: 34838239
Paraskevaidi M et al. Diagnostic Biomarkers for Alzheimer’s Disease Using Non-Invasive Specimens. J Clin Med, 2020. 9(6).
Lewczuk P, Łukaszewicz-Zając M, Mroczko P, Kornhuber J. Clinical significance of fluid biomarkers in Alzheimer’s disease. Pharmacol Rep. 2020;72(3):528–42.
Phadia-AB. Stool Extraction Kit plus / Stool Extraction Buffer plus, instruction for use: 200/250/2500/5000-6665-020 / UK, version 2021-09-14.. 2021; Available on https://dfu.phadia.com/Data/Pdf/6130cb9570eec660e274806b.pdf [Accessed 23 January 2023].].
ORGENTEC-Diagnostika-GmbH. Calprotectin, instruction for use: ORG 580_4, version ORG 580_IFU_EN_QM140866_2022-03-08_4. 2022; Available on https://products.orgentec.com/pdfs/ifu/ORG%20580_IFU_EN_QM140866_2022-03-08_4.pdf [Accessed 23 January 2023].].
Immundiagnostik-AG. IDK Hemoglobin ELISA: For the in vitro determination of hemoglobin in stool, instruction for use: K 7816D, K7816D.20, version 2022-02-22. 2022; Available on https://www.immundiagnostik.com/media/pages/testkits/k-7816d/9a63870b70-1663639307/k7816d_2022-02-22_haemoglobin.pdf [Accessed 23 January 2023].].
Demeditec-Diagnostics-GmbH. Calprotectin ELISA, instruction for use: DE849 V211014/DLB, version 2021-11-25.. 2021; Available on https://www.demeditec.de/de/produkte/calprotectin-elisa-de849/ifu-de849-calprotectin-elisa-211125-e.pdf [Accessed 23 January 2023].].
Bühlmann-Laboratories. Bühlmann Smart-Prep - Faecal sample preparation kit, Instruction for use: B-CAL-RD, version 2010-11-10. 2010; Available on https://www.buhlmannlabs.ch/wp-content/uploads/2015/01/B-CAL-RD_101110.pdf [Accessed 23 January 2023].].
Minic R, Zivkovic I. Optimization, Validation and Standardization of ELISA. 2020.
Schoonenboom NS, et al. Effects of processing and storage conditions on amyloid beta (1–42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem. 2005;51(1):189–95.
doi: 10.1373/clinchem.2004.039735
pubmed: 15539465
Yang T, et al. A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid. Alzheimers Res Ther. 2015;7(1):14.
doi: 10.1186/s13195-015-0100-y
pubmed: 25802556
pmcid: 4369838
Savage MJ, et al. A sensitive aβ oligomer assay discriminates Alzheimer’s and aged control cerebrospinal fluid. J Neurosci. 2014;34(8):2884–97.
doi: 10.1523/JNEUROSCI.1675-13.2014
pubmed: 24553930
pmcid: 6608513
Herskovits AZ, et al. A Luminex assay detects amyloid β oligomers in Alzheimer’s disease cerebrospinal fluid. PLoS ONE. 2013;8(7):e67898.
doi: 10.1371/journal.pone.0067898
pubmed: 23844122
pmcid: 3699502
Fukumoto H, et al. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. Faseb j. 2010;24(8):2716–26.
doi: 10.1096/fj.09-150359
pubmed: 20339023
Hölttä M, et al. Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer’s disease. PLoS ONE. 2013;8(6):e66381.
doi: 10.1371/journal.pone.0066381
pubmed: 23799095
pmcid: 3682966